ABUS vs JLL · P/E 5.4, rev $6.2M vs P/E 23, rev $23.43B
Arbutus Biopharma Corp (ABUS) versus Jones Lang LaSalle Incorporated (JLL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Not investment advice. Open the ABUS and JLL stock pages for the full models.
Not investment advice.